Stealth resubmits ultra-rare disease drug to FDA; Boehringer's retinal deal

Plus, news about SRT Therapeutics, Precigen, Enlivex, Tonix Pharmaceuticals and LakeShore Biopharma: Stealth BioTherapeutics resubmits its rare drug to the FDA: The privately held biotech’s experimental Barth syndrome drug was rejected by the regulator in ...